Founded in 2016, Maxwell Biosciences is a preclinical stage drug platform company actively developing an entirely new CLAROMER® biotechnology platform which creates low molecular weight compounds which mimic peptides and are functionally distinct from macromolecules due to the ease of penetrating membranes. 

This novel biotechnology mimics the power and flexibility of natural antimicrobial peptides - with the pharmacological advantages of a low molecular weight molecule - to safely and permanently inactivate viruses, bacteria, fungi and biofilms. Maxwell is led by a world-class team of scientists and executives.